{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:37:47Z","timestamp":1793227067561,"version":"4.5.0"},"reference-count":76,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venous thromboembolism (VTE) is a common complication in patients with brain tumors. The management of acute VTE is particularly challenging due to an elevated risk of intracranial hemorrhage (ICH). Risk of developing ICH on anticoagulation is influenced by a number of factors including tumor type, recent surgery, concomitant medications, platelet counts, and radiographic features. In patients with a heightened risk for ICH, the benefits of anticoagulation need to be balanced against a likelihood of developing major hemorrhagic complications. Management decisions include whether to administer anticoagulation, at what dose, placement of an inferior vena cava filter, monitoring for development of hemorrhage or progressive thrombus, and escalation of anticoagulant dose. This article discusses the complexities of treating acute VTE in patients with brain tumors and outlines treatment algorithms based on the presence or absence of ICH at the time of VTE diagnosis. Through case-based scenarios, we illustrate our approach to anticoagulation, emphasizing individualized risk assessments and evidence-based practices to optimize treatment outcomes while minimizing the risks of hemorrhagic events in patients with brain tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023450","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T19:12:50Z","timestamp":1724872370000},"page":"1781-1790","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["How I treat acute venous thromboembolism in\u00a0patients with brain tumors"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"first","affiliation":[{"name":"1Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-1360","authenticated-orcid":false,"given":"Jessica A.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[{"name":"1Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2024102415210398200_bib1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024102415210398200_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1215\/15228517-2006-035","article-title":"Venous thromboembolism and survival in patients with high-grade glioma","volume":"9","author":"Simanek","year":"2007","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024102415210398200_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2024102415210398200_bib4","doi-asserted-by":"crossref","first-page":"e0304682","DOI":"10.1371\/journal.pone.0304682","article-title":"Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: systematic review and meta-analysis","volume":"19","author":"Veiga","year":"2024","journal-title":"PLoS One"},{"issue":"13","key":"2024102415210398200_bib5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2024102415210398200_bib6","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024102415210398200_bib7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024102415210398200_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"2024102415210398200_bib9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024102415210398200_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2024102415210398200_bib11","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024102415210398200_bib12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024102415210398200_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"2","key":"2024102415210398200_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"2024102415210398200_bib15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"2024102415210398200_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2024102415210398200_bib17","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2024102415210398200_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024102415210398200_bib19","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024102415210398200_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2024102415210398200_bib21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A\u00a0meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024102415210398200_bib22","first-page":"473","article-title":"Spontaneous intracranial meningioma bleeding: clinicopathological features and outcome","volume":"103","author":"Bosnjak","year":"2005","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"2024102415210398200_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/cancers14030465","article-title":"Intracranial hemorrhage in patients with anticoagulant therapy undergoing stereotactic radiosurgery for brain metastases: a bi-institutional analysis","volume":"14","author":"Ehret","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"2024102415210398200_bib24","first-page":"43","article-title":"Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control","volume":"3","author":"Ghia","year":"2014","journal-title":"J\u00a0Radiosurg SBRT"},{"issue":"5","key":"2024102415210398200_bib25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/rth2.12377","article-title":"Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism","volume":"4","author":"Carney","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2024102415210398200_bib26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"2024102415210398200_bib27","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1182\/bloodadvances.2023011235","article-title":"Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation","volume":"7","author":"Iyengar","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2024102415210398200_bib28","first-page":"1849","article-title":"Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer","volume":"109","author":"Patell","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2024102415210398200_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ene.13830","article-title":"Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage","volume":"26","author":"Ianosi","year":"2019","journal-title":"Eur J Neurol"},{"issue":"5","key":"2024102415210398200_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jtha.2023.01.031","article-title":"Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors","volume":"21","author":"Ma","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024102415210398200_bib31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/bloodadvances.2021006470","article-title":"Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors","volume":"6","author":"Miller","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024102415210398200_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-017-2693-4","article-title":"Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis","volume":"137","author":"Yang","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"2024102415210398200_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-011-0642-1","article-title":"Safety of concurrent bevacizumab therapy\u00a0and anticoagulation in glioma patients","volume":"106","author":"Norden","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"4","key":"2024102415210398200_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2024102415210398200_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11060-022-04178-2","article-title":"Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases","volume":"160","author":"McKenzie","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"issue":"16","key":"2024102415210398200_bib36","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024102415210398200_bib37","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/cancers14102391","article-title":"Factors associated with hemorrhage of melanoma brain metastases after stereotactic radiosurgery in the era of targeted\/immune checkpoint inhibitor therapies","volume":"14","author":"Zoga","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024102415210398200_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-020-6569-1","article-title":"Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial","volume":"20","author":"Lesueur","year":"2020","journal-title":"BMC Cancer"},{"issue":"48","key":"2024102415210398200_bib39","doi-asserted-by":"crossref","first-page":"e28069","DOI":"10.1097\/MD.0000000000028069","article-title":"Clinico-radiological features of brain metastases from thyroid cancer","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2024102415210398200_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"2024102415210398200_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","article-title":"A\u00a0phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases","volume":"12","author":"Chevreau","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2024102415210398200_bib42","doi-asserted-by":"crossref","first-page":"e57691","DOI":"10.1371\/journal.pone.0057691","article-title":"Evaluating hemorrhage in renal cell carcinoma using susceptibility weighted imaging","volume":"8","author":"Xing","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"2024102415210398200_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.27.7.650","article-title":"Intracranial hemorrhage caused by metastatic tumors","volume":"27","author":"Mandybur","year":"1977","journal-title":"Neurology"},{"issue":"2","key":"2024102415210398200_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0090-4295(87)90175-0","article-title":"Hemorrhage: a complication of metastatic testicular choriocarcinoma","volume":"30","author":"Motzer","year":"1987","journal-title":"Urology"},{"issue":"25","key":"2024102415210398200_bib45","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"Mantia","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024102415210398200_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cancers15030619","article-title":"Associated factors of spontaneous hemorrhage in brain metastases in patients with lung adenocarcinoma","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024102415210398200_bib47","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1038\/s41598-020-67316-8","article-title":"Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"2024102415210398200_bib48","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a\u00a0meta-analysis of 85 randomized controlled trials","volume":"11","author":"Xiao","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"8","key":"2024102415210398200_bib49","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2024102415210398200_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jamacardio.2022.1988","article-title":"Clinical presentation and short- and long-term outcomes in patients with isolated distal deep vein thrombosis vs proximal deep vein thrombosis in the RIETE Registry","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2024102415210398200_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M21-2981","article-title":"Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation: a multicenter prospective cohort study","volume":"175","author":"Le Gal","year":"2022","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024102415210398200_bib52","first-page":"Cd013422","article-title":"Treatment of distal deep vein thrombosis","volume":"4","author":"Kirkilesis","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102415210398200_bib53","doi-asserted-by":"crossref","first-page":"e072623","DOI":"10.1136\/bmj-2022-072623","article-title":"Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial","volume":"379","author":"Ageno","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"2024102415210398200_bib54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.23.00429","article-title":"Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis","volume":"42","author":"Galanaud","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024102415210398200_bib55","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1055\/a-1742-0177","article-title":"Incidence and outcomes associated with 6,841 isolated distal deep vein thromboses in patients with 13 common cancers","volume":"122","author":"Mahajan","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024102415210398200_bib56","doi-asserted-by":"crossref","first-page":"109037","DOI":"10.1016\/j.thromres.2024.109037","article-title":"Risk of recurrent venous thromboembolism and bleeding in patients with acute isolated subsegmental pulmonary embolism","volume":"239","author":"Girardi","year":"2024","journal-title":"Thromb Res"},{"issue":"8","key":"2024102415210398200_bib57","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1055\/s-0039-1688828","article-title":"Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry","volume":"119","author":"Ageno","year":"2019","journal-title":"Thromb Haemost"},{"issue":"5","key":"2024102415210398200_bib58","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/jth.13291","article-title":"Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis","volume":"14","author":"Bleker","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024102415210398200_bib59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"2024102415210398200_bib60","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases","volume":"4","author":"Leader","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024102415210398200_bib61","doi-asserted-by":"crossref","first-page":"e12650","DOI":"10.1002\/rth2.12650","article-title":"Carbamazepine, phenytoin, and oral anticoagulants: drug-drug interaction and clinical events in a retrospective cohort","volume":"6","author":"Candeloro","year":"2022","journal-title":"Res\u00a0Pract Thromb Haemost"},{"issue":"12","key":"2024102415210398200_bib62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40263-019-00677-5","article-title":"Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"33","author":"Perlman","year":"2019","journal-title":"CNS Drugs"},{"key":"2024102415210398200_bib63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs","volume":"9","author":"Galgani","year":"2018","journal-title":"Front Neurol"},{"issue":"5","key":"2024102415210398200_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40263-024-01077-0","article-title":"The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations","volume":"38","author":"Goldstein","year":"2024","journal-title":"CNS Drugs"},{"issue":"2","key":"2024102415210398200_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.hest.2022.01.005","article-title":"Hemorrhage in brain tumor \u2013 an unresolved issue","volume":"3","author":"Ostrowski","year":"2022","journal-title":"Brain Hemorrhages"},{"issue":"1","key":"2024102415210398200_bib66","first-page":"11","article-title":"Imaging of intracranial hemorrhage","volume":"19","author":"Heit","year":"2017","journal-title":"J\u00a0Stroke"},{"issue":"1148","key":"2024102415210398200_bib67","doi-asserted-by":"crossref","first-page":"20220304","DOI":"10.1259\/bjr.20220304","article-title":"Susceptibility-weighted imaging in intracranial hemorrhage: not all bleeds are black","volume":"96","author":"Weerink","year":"2023","journal-title":"Br J Radiol"},{"issue":"12","key":"2024102415210398200_bib68","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study","volume":"24","author":"Reed-Guy","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024102415210398200_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/jnnp.54.5.466","article-title":"Early heparin therapy in patients with spontaneous intracerebral haemorrhage","volume":"54","author":"Boeer","year":"1991","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2024102415210398200_bib70","first-page":"166","article-title":"Early versus delayed initiation of pharmacological venous thromboembolism prophylaxis after an intracranial hemorrhage","volume":"22","author":"Faust","year":"2017","journal-title":"Neurol"},{"issue":"1","key":"2024102415210398200_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1749-7922-7-25","article-title":"Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage","volume":"7","author":"Byrnes","year":"2012","journal-title":"World J Emerg Surg"},{"issue":"1","key":"2024102415210398200_bib72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jss.2016.06.042","article-title":"Therapeutic anticoagulation in patients with traumatic brain injury","volume":"205","author":"Matsushima","year":"2016","journal-title":"J\u00a0Surg Res"},{"issue":"7","key":"2024102415210398200_bib73","doi-asserted-by":"crossref","first-page":"e2011942","DOI":"10.1001\/jamanetworkopen.2020.11942","article-title":"Evidence supporting the use of inferior vena cava filters in patients with cancer-coming into focus","volume":"3","author":"Barnes","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024102415210398200_bib74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"issue":"7","key":"2024102415210398200_bib75","doi-asserted-by":"crossref","first-page":"e2011079","DOI":"10.1001\/jamanetworkopen.2020.11079","article-title":"Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis","volume":"3","author":"Balabhadra","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2024102415210398200_bib76","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1055\/s-0040-1710589","article-title":"Outcomes after vena cava filter use in patients with cancer-associated venous thromboembolism and contraindications to anticoagulation","volume":"120","author":"Quezada","year":"2020","journal-title":"Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/17\/1781\/2246937\/blood_bld-2023-023450-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/17\/1781\/2246937\/blood_bld-2023-023450-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:21:26Z","timestamp":1729783286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/17\/1781\/517604\/How-I-treat-acute-venous-thromboembolism-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":76,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023450","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}